Comprehensive Stock Comparison
Compare Valneva SE (VALN) vs Scinai Immunotherapeutics Ltd. (SCNI) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | SCNI | 303.9% revenue growth vs VALN's 10.3% |
| Quality / Margins | SCNI | 401.8% net margin vs VALN's -34.1% |
| Stability / Safety | SCNI | Beta 0.60 vs VALN's 1.24, lower leverage |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | VALN | +64.3% vs SCNI's -74.9% |
| Efficiency (ROA) | SCNI | 38.9% ROA vs VALN's -14.2%, ROIC -61.1% vs 4.5% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Valneva is a specialty vaccine company developing and commercializing prophylactic vaccines for infectious diseases with unmet medical needs. It generates revenue primarily from sales of its commercial travel vaccines — IXIARO for Japanese encephalitis and DUKORAL for cholera — while advancing a pipeline of late-stage candidates including a chikungunya vaccine and a Lyme disease vaccine in partnership with Pfizer. The company's competitive advantage lies in its focus on niche infectious diseases often overlooked by larger pharmaceutical companies and its strategic partnerships that provide development funding and commercialization expertise.
Scinai Immunotherapeutics is a development-stage biopharmaceutical company focused on creating nanosized antibody therapies for infectious and autoimmune diseases. It generates revenue primarily through research collaborations and licensing agreements — notably with the Max Planck Society — while advancing its COVID-19 NanoAb and other pipeline candidates. The company's key advantage lies in its proprietary NanoAb platform technology, which aims to create smaller, potentially more effective antibody therapies compared to conventional antibodies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
VALN leads in 2 of 6 categories (Valuation Metrics, Total Returns). SCNI leads in 1 (Profitability & Efficiency). 2 tied.
Financial Metrics (TTM)
VALN is the larger business by revenue, generating $196M annually — 171.2x SCNI's $1M. SCNI is the more profitable business, keeping 4.0% of every revenue dollar as net income compared to VALN's -34.1%. On growth, SCNI holds the edge at +36.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | VALNValneva SE | SCNIScinai Immunother… |
|---|---|---|
| RevenueTrailing 12 months | $196M | $1M |
| EBITDAEarnings before interest/tax | -$36M | -$7M |
| Net IncomeAfter-tax profit | -$67M | $5M |
| Free Cash FlowCash after capex | -$34M | -$6M |
| Gross MarginGross profit ÷ Revenue | +49.0% | -147.0% |
| Operating MarginEBIT ÷ Revenue | -25.6% | -7.4% |
| Net MarginNet income ÷ Revenue | -34.1% | +4.0% |
| FCF MarginFCF ÷ Revenue | -17.5% | -5.0% |
| Rev. Growth (YoY)Latest quarter vs prior year | +27.0% | +36.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +60.5% | +66.7% |
Valuation Metrics
| Metric | VALNValneva SE | SCNIScinai Immunother… |
|---|---|---|
| Market CapShares × price | $963M | $3.0B |
| Enterprise ValueMkt cap + debt − cash | $1.0B | $3.0B |
| Trailing P/EPrice ÷ TTM EPS | -55.31x | 0.15x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 26.27x | — |
| Price / SalesMarket cap ÷ Revenue | 4.82x | 4607.73x |
| Price / BookPrice ÷ Book value/share | 3.64x | 0.07x |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
SCNI delivers a 58.7% return on equity — every $100 of shareholder capital generates $59 in annual profit, vs $-36 for VALN. SCNI carries lower financial leverage with a 0.21x debt-to-equity ratio, signaling a more conservative balance sheet compared to VALN's 1.19x.
| Metric | VALNValneva SE | SCNIScinai Immunother… |
|---|---|---|
| ROE (TTM)Return on equity | -36.0% | +58.7% |
| ROA (TTM)Return on assets | -14.2% | +38.9% |
| ROICReturn on invested capital | +4.5% | -61.1% |
| ROCEReturn on capital employed | +3.9% | -63.2% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 1.19x | 0.21x |
| Net DebtTotal debt minus cash | $48M | $122,000 |
| Cash & Equiv.Liquid assets | $168M | $2M |
| Total DebtShort + long-term debt | $216M | $2M |
| Interest CoverageEBIT ÷ Interest expense | -1.75x | 3.35x |
Total Returns (with DRIP)
A $10,000 investment in VALN five years ago would be worth $4,199 today (with dividends reinvested), compared to $20 for SCNI. Over the past 12 months, VALN leads with a +64.3% total return vs SCNI's -74.9%. The 3-year compound annual growth rate (CAGR) favors VALN at -1.8% vs SCNI's -66.5% — a key indicator of consistent wealth creation.
| Metric | VALNValneva SE | SCNIScinai Immunother… |
|---|---|---|
| YTD ReturnYear-to-date | +23.8% | +21.7% |
| 1-Year ReturnPast 12 months | +64.3% | -74.9% |
| 3-Year ReturnCumulative with dividends | -5.3% | -96.2% |
| 5-Year ReturnCumulative with dividends | -58.0% | -99.8% |
| 10-Year ReturnCumulative with dividends | -58.0% | -99.8% |
| CAGR (3Y)Annualised 3-year return | -1.8% | -66.5% |
Risk & Volatility
SCNI is the less volatile stock with a 0.60 beta — it tends to amplify market swings less than VALN's 1.24 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. VALN currently trades 90.5% from its 52-week high vs SCNI's 14.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | VALNValneva SE | SCNIScinai Immunother… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.24x | 0.60x |
| 52-Week HighHighest price in past year | $12.25 | $6.18 |
| 52-Week LowLowest price in past year | $5.43 | $0.61 |
| % of 52W HighCurrent price vs 52-week peak | +90.5% | +14.4% |
| RSI (14)Momentum oscillator 0–100 | 57.9 | 52.3 |
| Avg Volume (50D)Average daily shares traded | 14K | 42K |
Analyst Outlook
| Metric | VALNValneva SE | SCNIScinai Immunother… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | — |
| Price TargetConsensus 12-month target | $18.33 | — |
| # AnalystsCovering analysts | 2 | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | May 21 | Feb 26 | Change |
|---|---|---|---|
| Valneva SE (VALN) | 100 | 34.65 | -65.4% |
| Scinai Immunotherap… (SCNI) | 100 | 0.32 | -99.7% |
Valneva SE (VALN) returned -58% over 5 years vs Scinai Immunotherap… (SCNI)'s -100%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Valneva SE (VALN) | $78M | $170M | +116.4% |
| Scinai Immunotherap… (SCNI) | $0.00 | $658000.00 | — |
Valneva SE's revenue grew from $78M (2015) to $170M (2024) — a 9.0% CAGR. Scinai Immunotherapeutics Ltd.'s revenue grew from $0M (2015) to $1M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Valneva SE (VALN) | -26.3% | -7.2% | +72.6% |
| Scinai Immunotherap… (SCNI) | 7.3% | 7.3% | +0.0% |
Valneva SE's net margin went from -26% (2015) to -7% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Valneva SE (VALN) | -0.56 | -0.17 | +69.6% |
| Scinai Immunotherap… (SCNI) | -396,880 | 6 | +100.0% |
Valneva SE's EPS grew from $-0.56 (2015) to $-0.17 (2024). Scinai Immunotherapeutics Ltd.'s EPS grew from $-396880.00 (2015) to $6.00 (2024).
Chart 5Free Cash Flow — 5 Years
Valneva SE generated $-84M FCF in 2024 (-414% vs 2021). Scinai Immunotherapeutics Ltd. generated $-6M FCF in 2024 (+16% vs 2021).
VALN vs SCNI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is VALN or SCNI a better buy right now?
Scinai Immunotherapeutics Ltd. (SCNI) offers the better valuation at 0.1x trailing P/E, making it the more compelling value choice. Analysts rate Valneva SE (VALN) a "Buy" — based on 2 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — VALN or SCNI?
Over the past 5 years, Valneva SE (VALN) delivered a total return of -58.0%, compared to -99.8% for Scinai Immunotherapeutics Ltd. (SCNI). A $10,000 investment in VALN five years ago would be worth approximately $4K today (assuming dividends reinvested). Over 10 years, the gap is even starker: VALN returned -58.0% versus SCNI's -99.8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — VALN or SCNI?
By beta (market sensitivity over 5 years), Scinai Immunotherapeutics Ltd. (SCNI) is the lower-risk stock at 0.60β versus Valneva SE's 1.24β — meaning VALN is approximately 105% more volatile than SCNI relative to the S&P 500. On balance sheet safety, Scinai Immunotherapeutics Ltd. (SCNI) carries a lower debt/equity ratio of 21% versus 119% for Valneva SE — giving it more financial flexibility in a downturn.
04Which has better profit margins — VALN or SCNI?
Scinai Immunotherapeutics Ltd. (SCNI) is the more profitable company, earning 728.9% net margin versus -7.2% for Valneva SE — meaning it keeps 728.9% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VALN leads at 7.9% versus -1312.8% for SCNI. At the gross margin level — before operating expenses — VALN leads at 41.9%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — VALN or SCNI?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is VALN or SCNI better for a retirement portfolio?
For long-horizon retirement investors, Scinai Immunotherapeutics Ltd. (SCNI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.60)). Both have compounded well over 10 years (SCNI: -99.8%, VALN: -58.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between VALN and SCNI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. In terms of investment character: VALN is a small-cap quality compounder stock; SCNI is a small-cap deep-value stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.